Cirio advises Annexin in connection with its rights issue

Cirio Advokatbyrå AB advises Annexin Pharmaceuticals AB (publ), listed on Nasdaq First North Growth Market, in connection with its rights issue of units (consisting of shares and warrants) directed to the company’s existing shareholders.

An extraordinary general meeting held on October 8, 2021 resolved on the rights issue of units consisting of shares and warrants. The rights issue is fully secured through subscription and underwriting commitments and a prospectus has been approved and registered by the Swedish Financial Supervisory Authority.

Annexin is a world-leading biotechnology company in the Annexin A5 field, for treatment of various cardiovascular diseases, which today is the most common cause of death.

Cirio advises Annexin with a team headed by Per Hedman (Life science and Mergers & Acquisitions) and Maria Arnoldsson (Equity Capital Markets and Public M&A) together with Tim Johansson (Equity Capital Markets and Public M&A), and Fredrik Eliasson (Banking and Finance).

For more information, please contact: